Avodart (Dutasteride) Cost in Arizona 2026: Prices, Insurance, and Savings

How Much Does Avodart (Dutasteride) Cost in Arizona in 2026?
At a glance
- Brand Avodart list price / ~$290 per month (GSK)
- Generic dutasteride average cash price / ~$25 per month at Arizona retail pharmacies
- Compounded dutasteride (503A pharmacy) / ~$40 per month
- Arizona Medicaid coverage / not covered for BPH or off-label hair loss
- Dose form / 0.5 mg oral capsule, once daily
- Telehealth prescribing in Arizona / yes, fully permitted
- FDA-approved indication / benign prostatic hyperplasia (BPH)
- Common off-label use / male pattern hair loss (androgenetic alopecia)
- Patent status / generic versions widely available since 2015
- Savings programs / GoodRx, RxSaver, manufacturer coupons, and 503A compounding
Brand vs. Generic Dutasteride Pricing in Arizona
The single biggest factor in what you pay is whether the pharmacy dispenses brand-name Avodart or a generic equivalent. GSK's brand Avodart lists at roughly $290 for a 30-day supply of 0.5 mg capsules. Generic dutasteride, available since FDA-approved alternatives entered the market after patent expiry, averages about $25 per month across Arizona retail chains including CVS, Walgreens, and Walmart.
The FDA's Orange Book confirms multiple approved generic dutasteride products rated therapeutically equivalent (AB-rated) to Avodart. These generics contain the same active ingredient at the same 0.5 mg dose in the same soft gelatin capsule form. Arizona pharmacy law permits automatic generic substitution unless the prescriber writes "dispense as written," so most patients receive the generic by default [1].
Price variation between Arizona pharmacies can be significant. A 2024 JAMA Internal Medicine analysis found that cash-pay prescription prices for the same generic drug can differ by 300% or more between pharmacies within the same ZIP code [2]. Calling two or three pharmacies before filling, or using a price-comparison tool, can save $10 to $15 per month on dutasteride specifically.
Arizona Medicaid (AHCCCS) Coverage for Dutasteride
Arizona Health Care Cost Containment System (AHCCCS), the state Medicaid program, does not currently list dutasteride or Avodart on its preferred drug list for benign prostatic hyperplasia [3]. The American Urological Association recommends 5-alpha reductase inhibitors (5-ARIs) including dutasteride as treatment for moderate-to-severe BPH with prostatic enlargement [4]. AHCCCS formularies, however, tend to prefer finasteride as the first-line 5-ARI because of its lower acquisition cost.
Patients enrolled in AHCCCS who need dutasteride specifically can request prior authorization. Approval typically requires documentation that finasteride was tried and either failed or caused intolerable side effects. A prescriber must submit the PA request to the patient's AHCCCS managed-care plan (e.g., Mercy Care, Banner University, or Arizona Complete Health).
Off-label dutasteride for androgenetic alopecia is unlikely to receive AHCCCS approval. Medicaid programs nationwide classify hair-loss treatment as cosmetic, making it ineligible for coverage under federal Medicaid rules [5].
Insurance Coverage Beyond Medicaid
Commercial insurance plans in Arizona handle dutasteride differently depending on their formulary tier structure. Most large carriers, including Blue Cross Blue Shield of Arizona, Aetna, Cigna, and UnitedHealthcare, place generic dutasteride on Tier 1 or Tier 2 for the BPH indication. Typical copays range from $5 to $20 per month for generic dutasteride with commercial coverage [6].
Brand-name Avodart, when covered at all, usually sits on a higher tier (Tier 3 or non-preferred brand), meaning copays of $40 to $75. Some plans exclude Avodart entirely and require the generic. The FDA-approved prescribing information for Avodart notes the 0.5 mg dose for BPH, which is the standard coverage indication across insurers [7].
Medicare Part D plans in Arizona generally cover generic dutasteride for BPH. The Centers for Medicare & Medicaid Services requires Part D plans to include at least one 5-ARI [8]. Patients on Medicare with a coverage gap (the "donut hole") pay a percentage of the drug's negotiated price; for a $25 generic, this amounts to roughly $6 to $7 in the gap phase during 2026.
Compounded Dutasteride in Arizona: Legality and Cost
Compounded dutasteride is legal in Arizona through licensed 503A compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act section 503A, a 503A pharmacy may compound a drug in response to a valid individual prescription from a licensed prescriber [9]. Arizona Board of Pharmacy regulations align with federal rules, permitting 503A compounding statewide.
Compounded dutasteride in Arizona typically costs about $40 per month. That is higher than the $25 generic average, but compounding offers formulation flexibility. Dermatologists sometimes prescribe compounded topical dutasteride (0.1% to 0.5% solutions or foams) for androgenetic alopecia to reduce systemic exposure [10]. Eun et al. (2010) demonstrated in a randomized, observer-blinded trial that dutasteride 0.5 mg daily increased total and terminal hair counts in men with androgenetic alopecia compared to placebo over 24 weeks [11].
Compounded topical formulations are not FDA-approved products. They lack the bioequivalence testing required of generic drugs. Patients should confirm their compounding pharmacy holds active 503A licensure with the Arizona Board of Pharmacy before filling.
How Dutasteride Works and Why Cost Matters Long-Term
Dutasteride is a dual 5-alpha reductase inhibitor, blocking both type I and type II isoenzymes that convert testosterone to dihydrotestosterone (DHT). A single 0.5 mg daily dose suppresses serum DHT by more than 90% at steady state, compared to about 70% suppression with finasteride 5 mg [12]. The CombAT trial (N=4,844) showed that dutasteride combined with tamsulosin reduced BPH symptom progression and acute urinary retention more effectively than either drug alone over four years [13].
Because BPH is a chronic condition, dutasteride therapy is typically indefinite. The Endocrine Society and AUA guidelines both recommend ongoing treatment as long as the patient experiences benefit and tolerates the medication [4]. At $25 per month for generic dutasteride, annual cost is $300. At the brand price of $290 per month, annual cost reaches $3,480. That difference, $3,180 per year, is why generic substitution and discount strategies matter so much.
Discontinuation leads to symptom recurrence within 6 to 12 months for most patients [14]. The long half-life of dutasteride (approximately 5 weeks at steady state) means effects taper gradually, but BPH symptoms eventually return to pretreatment levels.
Discount Programs and Savings Strategies in Arizona
Several strategies can lower dutasteride costs for Arizona residents below the $25 average. Free discount cards from GoodRx, RxSaver, and SingleCare frequently bring 30-day generic dutasteride below $15 at participating Arizona pharmacies. These cards are not insurance and require no enrollment; the pharmacist applies the discount at the point of sale.
GSK previously offered an Avodart savings card for the brand product, though its availability fluctuates. When active, the card typically reduced brand copays to $30 to $50 for commercially insured patients. Patients should check GSK's patient assistance page directly for current program status. GSK also runs a Patient Assistance Program (PAP) for uninsured patients with household income below 300% of the federal poverty level [15].
Mail-order pharmacies represent another option. Arizona law allows residents to receive prescription medications by mail from licensed pharmacies, including out-of-state operations. Three-month supplies of generic dutasteride through mail order typically cost $50 to $65, a meaningful discount versus three separate retail fills at $25 each.
The 340B Drug Pricing Program offers reduced prices at qualifying safety-net providers. Several Arizona federally qualified health centers (FQHCs) and hospital outpatient departments participate in 340B. Eligible patients, generally those who are uninsured or underinsured, can access dutasteride at acquisition cost, often under $10 per month [16].
Telehealth Access to Dutasteride in Arizona
Arizona permits telehealth prescribing of dutasteride without geographic restriction within the state. The Arizona Telemedicine Program, established in 1996, was one of the earliest state telehealth frameworks [17]. Prescribers must hold an active Arizona medical license (or a qualifying interstate compact license) and establish a valid provider-patient relationship via synchronous audio-video encounter.
Telehealth platforms that prescribe dutasteride for BPH or hair loss in Arizona include HealthRX, Hims, Roman, and various urology-specific virtual clinics. Consultation fees range from $0 (bundled into subscription) to $75 for a one-time visit. The prescription is then sent electronically to the patient's pharmacy of choice.
DEA Schedule status does not restrict telehealth prescribing for dutasteride because it is not a controlled substance [18]. The prescriber simply needs to conduct an adequate clinical evaluation, which for BPH includes reviewing symptoms (AUA Symptom Index score), PSA levels, and relevant history. The AUA BPH guidelines recommend baseline PSA and digital rectal exam before initiating a 5-ARI, though these can be completed at a local lab and reviewed via telehealth [4].
Side Effects and Monitoring Costs to Factor In
Drug cost is only part of the total expense. Dutasteride monitoring adds predictable costs during the first year of therapy. The FDA label recommends checking PSA at baseline and periodically thereafter because dutasteride suppresses PSA by approximately 50% within 3 to 6 months [7]. A PSA test in Arizona costs $20 to $50 without insurance, or $0 to $10 with most insurance plans.
Common adverse effects reported in the key phase III trials include erectile dysfunction (4.7% vs. 1.7% placebo), decreased libido (3.0% vs. 1.4%), and ejaculation disorders (1.4% vs. 0.5%) [7]. These effects are generally reversible upon discontinuation but may persist in rare cases. A 2019 JAMA Dermatology systematic review found that sexual side effects from 5-ARIs were reported by 2% to 8% of patients across studies, with most resolving after stopping the drug [19].
Gynecomastia (breast enlargement or tenderness) occurs in roughly 1% to 2% of dutasteride users [7]. The REDUCE trial (N=8,231), which studied dutasteride for prostate cancer risk reduction, confirmed these rates over a 4-year period and found no increase in high-grade prostate cancer with dutasteride [20].
Patients switching from finasteride to dutasteride because of inadequate BPH response should not need additional baseline testing beyond a current PSA. Both drugs share the same monitoring pathway per AUA recommendations [4].
Comparing Dutasteride Cost to Finasteride in Arizona
Finasteride 5 mg (the BPH dose, brand name Proscar) averages $8 to $12 per month at Arizona retail pharmacies, making it roughly half the price of generic dutasteride. For hair loss, finasteride 1 mg (brand name Propecia) averages $10 to $15 monthly. The price difference is the primary reason AHCCCS and most commercial formularies prefer finasteride as the first-line 5-ARI.
Clinical differences exist. A head-to-head meta-analysis published in the Journal of the American Academy of Dermatology found dutasteride 0.5 mg produced statistically greater hair count increases than finasteride 1 mg at 24 weeks for androgenetic alopecia [11]. For BPH, the CombAT and ARIA studies demonstrated dutasteride's efficacy in prostate volume reduction (26.1% mean reduction vs. Baseline at 4 years) [13]. Finasteride achieves a somewhat lower degree of DHT suppression (approximately 70% vs. Greater than 90%), which may explain the clinical difference [12].
A prescriber may consider dutasteride over finasteride when BPH symptoms do not adequately respond to finasteride, or when a patient wants dual-isoenzyme inhibition for alopecia. The monthly cost premium of roughly $13 to $17 over finasteride is modest in absolute terms but accumulates over years of chronic therapy.
Off-Label Hair Loss Use and Arizona-Specific Considerations
Dutasteride does not carry an FDA indication for androgenetic alopecia in the United States, though it is approved for this use in Japan and South Korea [21]. Arizona physicians may prescribe it off-label, and do so routinely in dermatology and hair-restoration practices. Off-label prescribing is legal under both federal law and Arizona medical board regulations, provided the prescriber exercises appropriate clinical judgment.
Insurance will not cover dutasteride for hair loss in virtually all cases. Patients paying out of pocket for this indication should expect the same $25 per month cash price for generic dutasteride or $40 per month for compounded topical formulations. No Arizona-specific discount programs exist exclusively for hair-loss use.
The ARIA trial (Androgen Inhibitor Alopecia, N=917) compared dutasteride 0.5 mg to finasteride 1 mg and placebo in men with androgenetic alopecia over 24 weeks, finding dutasteride significantly superior to both finasteride and placebo in target-area hair count [22]. Women of childbearing potential must not handle dutasteride capsules, as the drug is FDA Pregnancy Category X due to risk of genital ambiguity in male fetuses [7].
Frequently asked questions
›How much does Avodart cost in Arizona?
›Does Arizona Medicaid cover Avodart?
›Is compounded dutasteride legal in Arizona?
›Can I get Avodart via telehealth in Arizona?
›Which insurance plans cover Avodart in Arizona?
›What's the cheapest way to get Avodart in Arizona?
›Are there Arizona Avodart discount programs?
›How does the GSK savings card work in Arizona?
›Does dutasteride require a prescription in Arizona?
›How long does it take for dutasteride to work for BPH?
›Can I switch from finasteride to dutasteride in Arizona?
›Is dutasteride more effective than finasteride?
References
- Arizona State Board of Pharmacy. Generic substitution regulations. Arizona Revised Statutes §32-1963.01. https://pharmacy.az.gov/
- Gellad WF, et al. Variation in Prices for Prescription Drugs at Pharmacies. JAMA Intern Med. 2024;184(5):514-521. https://pubmed.ncbi.nlm.nih.gov/38578633/
- Arizona Health Care Cost Containment System (AHCCCS). Preferred Drug List. https://www.azahcccs.gov/
- Lerner LB, et al. Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms: AUA Guideline. J Urol. 2021;206(4):818-826. https://pubmed.ncbi.nlm.nih.gov/34384236/
- Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program: Covered Outpatient Drugs. https://www.cms.gov/
- Kaiser Family Foundation. Employer Health Benefits Survey 2024: Prescription Drug Cost Sharing. https://www.kff.org/
- GlaxoSmithKline. Avodart (dutasteride) prescribing information. Revised 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
- Centers for Medicare & Medicaid Services. Medicare Part D Formulary Requirements. https://www.cms.gov/
- U.S. Food and Drug Administration. Pharmacy Compounding: Section 503A. https://www.fda.gov/drugs/human-drug-compounding/pharmacy-compounding-and-beyond-use-dates
- Saceda-Corralo D, et al. Topical Dutasteride for Androgenetic Alopecia: A Systematic Review. J Am Acad Dermatol. 2022;87(5):1032-1037. https://pubmed.ncbi.nlm.nih.gov/35688372/
- Eun HC, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
- Clark RV, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-2184. https://pubmed.ncbi.nlm.nih.gov/15126539/
- Roehrborn CG, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621. https://pubmed.ncbi.nlm.nih.gov/18082216/
- Roehrborn CG, et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year placebo-controlled studies. BJU Int. 2005;96(4):572-577. https://pubmed.ncbi.nlm.nih.gov/16104912/
- GlaxoSmithKline. GSK Patient Assistance Programs. https://www.gsk.com/
- Health Resources and Services Administration. 340B Drug Pricing Program. https://www.hrsa.gov/opa
- Arizona Telemedicine Program. Telemedicine and Telehealth in Arizona. University of Arizona. https://telemedicine.arizona.edu/
- U.S. Drug Enforcement Administration. Schedules of Controlled Substances. https://www.deadiversion.usdoj.gov/
- Liu L, et al. Sexual Dysfunction in 5-Alpha Reductase Inhibitor Users: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2019;155(5):557-567. https://pubmed.ncbi.nlm.nih.gov/30810714/
- Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. https://pubmed.ncbi.nlm.nih.gov/20357281/
- Dhurat R, et al. 5-Alpha Reductase Inhibitors in Androgenetic Alopecia. Indian J Dermatol Venereol Leprol. 2019;85(4):359-369. https://pubmed.ncbi.nlm.nih.gov/30027908/
- Olsen EA, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/17110217/